Date Mailed: June 26, 2002

Sheet 1 of 2

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 131.3-US-WO	Application Number: 10/031,639
	Applicant: Luigi Naldini et al.	
	Filing Date: October 29, 2001	Group Art Unit: ~~To Be Assigned~~ 1636

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JR	5,503,974	04/02/96	Gruber et al.			
DZ	5,583,022	12/10/96	Heidmann et al.			
DT	5,591,579	01/07/97	Olivo et al.			
DT	5,614,404	03/25/97	Mazzara et al.			
DT	5,650,309	07/22/97	Wong-Staal et al.			
DT	5,665,577	09/09/97	Sodroski et al.			
DT	5,681,746	10/28/97	Bodner et al.			
DT	5,693,508	12/02/97	Chang			
DT	5,716,613	02/10/98	Guber et al.			
DT	5,716,826	02/10/98	Gruber et al.			
DT	5,739,118	04/14/98	Carrano et al.			
DT	5,747,307	05/05/98	Lever et al.			
DT	5,994,136	11/30/99	Naldini et al.			

FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
JR	WO 99/31251	06/24/99	PCT				
DT	WO 99/04026	01/28/99	PCT				
DT	WO 98/12314	03/26/98	PCT				
DT	EP 0 759 471 A1	02/26/97	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
JR		Berkhout et al., "Tat Transactivates the Human Immunodeficiency Virus Through a Nascent RNA Target," Cell, 1989, vol. 59: 273-282
DT		Blomer et al., "Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector," Jnl. of Virology, Sept. 1997, vol. 71(9): 6641-6649
DT		A. Bukovsky et al., "Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells," Jnl. of Virology, Aug. 1999, vol. 73(8): 7087-7092
DT		L-J Chang et al., "Efficacy and Safety Analyses of a Recombinant Human Immunodeficiency Virus Type 1 Derived Vector System," Gene Therapy, 1999, vol. 6: 715-728

EXAMINER: David Huynh	DATE CONSIDERED: 11/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 131.3-US-WO

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: G&C 131.3-US-WO	Application Number: 10/031,639
	Applicant: Luigi Naldini et al.	
	Filing Date: October 29, 2001	Group Art Unit: ~~To Be Assigned~~ 1636

		JM Coffin, Fundamental Virology, 1996, 3rd Edition (Fields et al., eds), Chapter 26, "*Retroviridae*: The Viruses and Their Replication," pp. 763-843, Lipincott-Raven Publishers, Philadelphia, PA
		T. Dull et al., "A Third Generation Lentivirus Vector with a Conditional Packaging System," Jnl. of Virology, Nov. 1998, vol. 72(11): 8463-8471
		Elder et al., "Feline Immunodeficiency Virus as a Model for Development of Molecular Approaches to Intervention Strategies Against Lentivirus Infections," Adv. Virus Res., Vol. 45: pp. 225-247
		D. Farson et al., "Large-Scale Manufacturing of Safe and Efficient Rerovirus Packaging Lines for Use in Immunotherapy Protocols," Jnl. of Gene Medicine, 1999, vol. 1: 195-209
		N. Ferry et al., "Liver-Directed Gene Transfer Vectors," Human Gene Therapy, Sept. 1998, vol. 9: 1975-1981
		M. Gasmi et al., "Requirements for Efficient Production and Transduction of Human Immunodeficiency Virus Type 1-Based Vectors," Jnl. of Virology, March 1999, vol. 73(3): 1828-1834
		T. Kafri et al., "Sustained Expression of Genes Delivered Directly Into Liver and Muscle by Lentiviral Vectors," Nature Genetics, Nov. 1997, vol. 17: 314-317
		G. Kalpana, "Retroviral Vectors for Liver-Directed Gene Therapy," Seminars in Liver Disease, 1999, vol. 19(1): 27-37
		Kim et al., "Construction of Retroviral Vectors with Improved Safety, Gene Expression, and Versatility," Jnl. of Virology, Feb. 1998, vol. 72(2): 994-1004
		Lisziewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication By Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," Proc. Natl. Acad. Sci. USA, 1993, vol. 90: 8000-8004
		H. Miyoshi et al., "Development of a Self-Inactivating Lentivirus Vector," Jnl. of Virology, Oct. 1998, vol. 72(10): 8150-8157
		L. Naldini et al., "Efficient Transfer, Integration, and Sustained Long-Term Expression of the Transgene in Adult Rat Brains Injected with a Lentiviral Vector," Proc. Natl. Acad. Sci. USA, Oct. 1996, vol. 93: 11382-11388
		L. Naldini et al., "In Vivo Gene Delivery and Stable Transduction of Nondiving Cells by a Lentiviral Vector," Science, April 1996, vol. 272: 263-267
		D. Ory et al., "A Stable Human-Derived Packaging Cell Line for Production of High Titer Retrovirus/Vesicular Stomatitias Virus G Pseudotypes," Proc. Natl. Acad. Sci. USA, Oct. 1996, vol. 93: 11400-11406
		R. Schneider et al., "Inactivation of the Human Immunodeficiency Virus Type I Inhibitory Elements Allows Rev-Independent Expression of Gag and Gag/Protease and Particle Formation," Jnl. of Virology, July 1997, vol. 71(7): 4892-4903
		R. Zufferey et al., "Multiply Attenuated Lentiviral Vector Achieves Efficient Gene Delivery In Vivo," Nature Biotechnology, Sept. 1997, vol. 15: 871-875
		R. Zufferey et al., "Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery," Jnl. of Virology, Dec. 1998, vol. 72(12): 9873-9880

EXAMINER: David Romeo	DATE CONSIDERED: 11/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

G&C 131.3-US-WO